SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
ZUG, Switzerland, March 29, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017, at 11:20 am Eastern Time in New York City. A live webcast of the event will be available through the Events and Presentations page in the Investors section of the Auris Medical website at www.aurismedical.com, and a replay of the presentation will be available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, [email protected]
